(Q37842543)

24 August 2017

1 reference

title

The potential role of nemonoxacin for treatment of common infections (English)

1 reference

24 August 2017

4

Po-Ren Hsueh

1 reference

24 August 2017

Chung-Hao Huang

1

1 reference

24 August 2017

Chung-Chih Lai

series ordinal

2

1 reference

24 August 2017

Yen-Hsu Chen

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 December 2014

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

263-270

1 reference

Impact of antibiotic resistance on clinical outcomes and the cost of care

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

The true cost of antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Nemonoxacin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

The changing epidemiology of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Fidaxomicin: a review of its use in patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Overview of severe Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Quinolone resistance: much more than predicted.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Trends in US hospital admissions for skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Methicillin-resistant Staphylococcus aureus in community-acquired skin infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Novel antibiotic treatment for skin and soft tissue infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Cold-induced stress increases the intensity of Chlamydia genital infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

The emerging threat of untreatable gonococcal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

Updated antibiotic resistance and clinical spectrum of infections caused by Streptococcus pneumoniae in Taiwan: Emphasis on risk factors for penicillin nonsusceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978288

10.1517/14656566.2015.978288

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference